

Dear Hannah,

On behalf of the ADEPT committee, thank you very much for submitting your protocol "D3250R00042 Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study". Please see below reference details for your application.

Date of Application	12/10/2020
Date of Approval	02/11/2020
Approval Type	Chair approval
Title of Research Database	ISAR
Title of Protocol	D3250R00042 Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study
ADEPT Protocol Reference	PROTOCOL2284
ADEPT Approval Reference	ADEPT1420
Lead Investigator & Contact details	Prof Trung Tran trung.tran@astrazeneca.com

On behalf of the ADEPT committee, I am pleased to **approve** your protocol named above.

We wish you all the best with this and any future work undertaken by you and your organisation.

Yours Sincerely



Dr Todor Popov (ADEPT Chair)